ArticleBriefings in bioinformatics2024
Directed evolution of antimicrobial peptides using multi-objective zeroth-order optimization.
Article in Briefings in bioinformatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Generative AI for controllable protein sequence design: A survey.npj drug discovery · 2026Review
- Data-Driven Engineering of Antimicrobial Nanomaterials for Food Safety and Biomedical Systems.Nanomaterials (Basel, Switzerland) · 2026Review
- Heuristic multi-site optimization for protein sequence design using Masked Protein Language Models.PLoS computational biology · 2026Article
- Artificial Intelligence-Driven Discovery and Optimization of Antimicrobial Peptides Targeting ESKAPE Pathogens and Multidrug-Resistant Fungi.Microorganisms · 2026Review
- PepLM-GNN: A graph neural network framework leveraging pre-trained language models for peptide-protein binding prediction.PLoS computational biology · 2026Article
- Recent advances in multimodal foundation model-enabled peptide screening and optimization for smart biomaterials and functional tissue engineering.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Antimicrobial peptides (AMPs) emerge as a type of promising therapeutic compounds that exhibit broad spectrum antimicrobial activity with high specificity and good tolerability. Natural AMPs usually need further rational design for improving antimicrobial activity and decreasing toxicity to human cells. Although several algorithms have been developed to optimize AMPs with desired properties, they explored the variations of AMPs in a discrete amino acid sequence space, usually suffering from low efficiency, lack diversity, and local optimum. In this work, we propose a novel directed evolution method, named PepZOO, for optimizing multi-properties of AMPs in a continuous representation space guided by multi-objective zeroth-order optimization. PepZOO projects AMPs from a discrete amino acid sequence space into continuous latent representation space by a variational autoencoder. Subsequently, the latent embeddings of prototype AMPs are taken as start points and iteratively updated according to the guidance of multi-objective zeroth-order optimization. Experimental results demonstrate PepZOO outperforms state-of-the-art methods on improving the multi-properties in terms of antimicrobial function, activity, toxicity, and binding affinity to the targets. Molecular docking and molecular dynamics simulations are further employed to validate the effectiveness of our method. Moreover, PepZOO can reveal important motifs which are required to maintain a particular property during the evolution by aligning the evolutionary sequences. PepZOO provides a novel research paradigm that optimizes AMPs by exploring property change instead of exploring sequence mutations, accelerating the discovery of potential therapeutic peptides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.